An Optimised Indirect ELISA Protocol for Detection and Quantification of Anti-viral Antibodies in Human Plasma or Serum: A Case Study Using SARS-CoV-2

被引：4

作者：

Baine, Claire ^{[1
]}

Sembera, Jackson ^{[1
,2
,3
]}

Oluka, Gerald Kevin ^{[1
,2
,3
]}

Katende, Joseph Ssebwana ^{[1
,2
,3
]}

Ankunda, Violet ^{[1
,2
,3
]}

Serwanga, Jennifer ^{[1
,2
,3
]}

机构：

[1] Uganda Virus Res Inst, Dept Immunol, Entebbe, Uganda

[2] Uganda Virus Res Inst, Med Res Council, Entebbe, Uganda

[3] London Sch Hyg & Trop Med, Uganda Res Unit, Entebbe, Uganda

来源：

BIO-PROTOCOL | 2023年 / 13卷 / 24期

基金：

英国医学研究理事会;

关键词：

ELISA; SARS-CoV-2; Viral infections; Optical densities; Antibody concentrations; RESPONSES;

D O I：

10.21769/BioProtoc.4905

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Advanced immunoassays are crucial in assessing antibody responses, serving immune surveillance goals, characterising immunological responses to evolving viral variants, and guiding subsequent vaccination initiatives. This protocol outlines an indirect ELISA protocol to detect and quantify virus-specific antibodies in plasma or serum after exposure to viral antigens. The assay enables the measurement of IgG, IgA, and IgM antibodies specific to the virus of interest, providing qualitative and quantitative optical densities and concentration data. Although this protocol refers to SARS-CoV-2, its methodology is versatile and can be modified to assess antibody responses for various viral infections and to evaluate vaccine trial outcomes.

引用

页数：29

共 11 条

[1] Temporal trends and differences of SARS-CoV-2-specific antibody responses in symptomatic and asymptomatic subjects: a longitudinal study from Umbria in Italy [J].

Abraha, Iosief ;

Eusebi, Paolo ;

Germani, Antonella ;

Pasquarelli, Erica ;

Pascolini, Sofia ;

Antonietti, Rossana ;

Argenti, Sandro ;

Fioravanti, Alessandra ;

Martini, Elisa ;

Aristei, Luana ;

Mancinelli, Paola ;

Ottaviani, Maria Letizia ;

Roselli, Martina ;

Barzacca, Milena ;

Belardinelli, Erika ;

Micheli, Marta .

BMJ OPEN, 2022, 12 (07)

[2] Durability of Antibody Responses to SARS-CoV-2 Infection and Its Relationship to Disease Severity Assessed Using a Commercially Available Assay [J].

Alshami, Alanoud ;

Al Attas, Rabab ;

Anan, Hadeel ;

Al Maghrabi, Aroub ;

Ghandorah, Salim ;

Mohammed, Amani ;

Alhalimi, Abdulbary ;

Al-Jishi, Jumana ;

Alqahtani, Hadi .

FRONTIERS IN MICROBIOLOGY, 2021, 12

[3] Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+T cell responses [J].

Balachandran, Harikrishnan ;

Phetsouphanh, Chansavath ;

Agapiou, David ;

Adhikari, Anurag ;

Rodrigo, Chaturaka ;

Hammoud, Mohamed ;

Shrestha, Lok Bahadur ;

Keoshkerian, Elizabeth ;

Gupta, Money ;

Turville, Stuart ;

Christ, Daniel ;

King, Cecile ;

Sasson, Sarah C. ;

Bartlett, Adam ;

Grubor-Bauk, Branka ;

Rawlinson, William ;

Aggarwal, Anupriya ;

Stella, Alberto Ospina ;

Klemm, Vera ;

Mina, Michael M. ;

Post, Jeffrey J. ;

Hudson, Bernard ;

Gilroy, Nicky ;

Konecny, Pam ;

Ahlenstiel, Golo ;

Dwyer, Dominic E. ;

Sorrell, Tania C. ;

Kelleher, Anthony ;

Tedla, Nicodemus ;

Lloyd, Andrew R. ;

Martinello, Marianne ;

Bull, Rowena A. .

CELL REPORTS, 2022, 38 (06)

[4] A Reliable Indirect ELISA Protocol for Detection of Human Antibodies Directed to SARS-CoV-2 NP Protein [J].

Faizo, Arwa A. ;

Alandijany, Thamir A. ;

Abbas, Ayman T. ;

Sohrab, Sayed S. ;

El-Kafrawy, Sherif A. ;

Tolah, Ahmed M. ;

Hassan, Ahmed M. ;

Azhar, Esam I. .

DIAGNOSTICS, 2021, 11 (05)

[5] A phase I COVID-19 vaccine trial among SARS-CoV-2 seronegative and seropositive individuals in Uganda utilizing a self-amplifying RNA vaccine platform: Screening and enrollment experiences [J].

Kitonsa, Jonathan ;

Kamacooko, Onesmus ;

Ruzagira, Eugene ;

Nambaziira, Florence ;

Abaasa, Andrew ;

Serwanga, Jennifer ;

Gombe, Ben ;

Lunkuse, Jane ;

Naluyinda, Hadijah ;

Tukamwesiga, Naboth ;

Namata, Tamara ;

Kigozi, Antony ;

Kafeero, Paddy ;

Basajja, Vincent ;

Joseph, Sarah ;

Pierce, Benjamin F. ;

Shattock, Robin ;

Kaleebu, Pontiano .

HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (02)

[6] Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection [J].

Marchi, Serena ;

Viviani, Simonetta ;

Remarque, Edmond J. ;

Ruello, Antonella ;

Bombardieri, Emilio ;

Bollati, Valentina ;

Milani, Gregorio P. ;

Manenti, Alessandro ;

Lapini, Giulia ;

Rebuffat, Annunziata ;

Montomoli, Emanuele ;

Trombetta, Claudia M. .

PLOS ONE, 2021, 16 (07)

[7]

Nantambi H., 2023, Front. Immunol., V14

[8] Optimisation and Validation of a conventional ELISA and cut-offs for detecting and quantifying anti-SARS-CoV-2 Spike, RBD, and Nucleoprotein IgG, IgM, and IgA antibodies in Uganda [J].

Oluka, Gerald Kevin ;

Namubiru, Patricia ;

Kato, Laban ;

Ankunda, Violet ;

Gombe, Ben ;

Cotten, Matthew ;

Musenero, Monica ;

Kaleebu, Pontiano ;

Fox, Julie ;

Serwanga, Jennifer .

FRONTIERS IN IMMUNOLOGY, 2023, 14

[9]

Serwanga J., 2023, Front. Immunol, V14

[10] Seroprevalence and durability of antibody responses to AstraZeneca vaccination in Ugandans with prior mild or asymptomatic COVID-19: implications for vaccine policy [J].

Serwanga, Jennifer ;

Baine, Claire ;

Mugaba, Susan ;

Ankunda, Violet ;

Auma, Betty Oliver ;

Oluka, Gerald Kevin ;

Kato, Laban ;

Kitabye, Isaac ;

Sembera, Jackson ;

Odoch, Geoffrey ;

Ejou, Peter ;

Nalumansi, Amina ;

Gombe, Ben ;

Musenero, Monica ;

Kaleebu, Pontiano .

FRONTIERS IN IMMUNOLOGY, 2023, 14

← 1 2 →